{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:46:23Z","timestamp":1788306383705,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T00:00:00Z","timestamp":1536969600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12876-018-0868-x","type":"journal-article","created":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T00:50:43Z","timestamp":1537059043000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Vedolizumab use after failure of TNF-\u03b1 antagonists in children and adolescents with inflammatory bowel disease"],"prefix":"10.1186","volume":"18","author":[{"given":"Anna-Maria","family":"Schneider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Weghuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Hetzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Entenmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Sch\u00fctz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf-Dietrich","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,15]]},"reference":[{"issue":"9573","key":"868_CR1","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(07)60750-8","volume":"369","author":"DC Baumgart","year":"2007","unstructured":"Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369(9573):1627\u201340.","journal-title":"Lancet"},{"issue":"5","key":"868_CR2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ijmm.2016.03.003","volume":"306","author":"C Gunther","year":"2016","unstructured":"Gunther C, Josenhans C, Wehkamp J. Crosstalk between microbiota, pathogens and the innate immune responses. Int J Med Microbiol. 2016;306(5):257\u201365.","journal-title":"Int J Med Microbiol"},{"issue":"10","key":"868_CR3","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.crohns.2014.04.005","volume":"8","author":"FM Ruemmele","year":"2014","unstructured":"Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO\/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis. 2014;8(10):1179\u2013207.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"868_CR4","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","volume":"132","author":"J Hyams","year":"2007","unstructured":"Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007;132(3):863\u201373. quiz 1165-6","journal-title":"Gastroenterology"},{"issue":"2","key":"868_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1053\/j.gastro.2012.04.046","volume":"143","author":"JS Hyams","year":"2012","unstructured":"Hyams JS, Griffiths A, Markowitz J, et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology. 2012;143(2):365\u201374. e2","journal-title":"Gastroenterology"},{"issue":"7","key":"868_CR6","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/apt.13083","volume":"41","author":"JP Gisbert","year":"2015","unstructured":"Gisbert JP, Marin AC, McNicholl AG, et al. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015;41(7):613\u201323.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"868_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3109\/00365521.2012.741619","volume":"48","author":"A Hamalainen","year":"2013","unstructured":"Hamalainen A, Sipponen T. Kolho KL serum infliximab concentrations in pediatric inflammatory bowel disease. Scand J Gastroenterol. 2013;48(1):35\u201341.","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"868_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","volume":"146","author":"WJ Sandborn","year":"2014","unstructured":"Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):85\u201395. quiz e14\u20135","journal-title":"Gastroenterology"},{"issue":"4","key":"868_CR9","first-page":"400","volume":"11","author":"EV Loftus Jr","year":"2017","unstructured":"Loftus EV Jr, Colombel JF, Feagan BG, et al. Long-term efficacy of Vedolizumab for ulcerative colitis. J Crohns Colitis. 2017;11(4):400\u201311.","journal-title":"J Crohns Colitis"},{"issue":"5","key":"868_CR10","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1097\/MIB.0000000000000396","volume":"21","author":"MH Mosli","year":"2015","unstructured":"Mosli MH, MacDonald JK, Bickston SJ, et al. Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis. Inflamm Bowel Dis. 2015;21(5):1151\u20139.","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"868_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369(8):711\u201321.","journal-title":"N Engl J Med"},{"issue":"4","key":"868_CR12","first-page":"412","volume":"11","author":"S Vermeire","year":"2017","unstructured":"Vermeire S, Loftus EV Jr, Colombel JF, et al. Long-term efficacy of Vedolizumab for Crohn's disease. J Crohns Colitis. 2017;11(4):412\u201324.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"868_CR13","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","volume":"147","author":"BE Sands","year":"2014","unstructured":"Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):618\u201327. e3","journal-title":"Gastroenterology"},{"issue":"10","key":"868_CR14","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1097\/MIB.0000000000000918","volume":"22","author":"MA Conrad","year":"2016","unstructured":"Conrad MA, Stein RE, Maxwell EC, et al. Vedolizumab therapy in severe pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(10):2425\u201331.","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"868_CR15","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1097\/MIB.0000000000000865","volume":"22","author":"N Singh","year":"2016","unstructured":"Singh N, Rabizadeh S, Jossen J, et al. Multi-center experience of Vedolizumab effectiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(9):2121\u20136.","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"868_CR16","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/ecco-jcc\/jjx082","volume":"11","author":"O Ledder","year":"2017","unstructured":"Ledder O, Assa A, Levine A, et al. Vedolizumab in pediatric inflammatory bowel disease: a retrospective multi-center experience from the Paediatric IBD Porto group of ESPGHAN. J Crohns Colitis. 2017;11(10):1230\u20137.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"868_CR17","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/ibd.21452","volume":"17","author":"MD Kappelman","year":"2011","unstructured":"Kappelman MD, Crandall WV, Colletti RB, et al. Short pediatric Crohn's disease activity index for quality improvement and observational research. Inflamm Bowel Dis. 2011;17(1):112\u20137.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"868_CR18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1053\/j.gastro.2007.05.029","volume":"133","author":"D Turner","year":"2007","unstructured":"Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007;133(2):423\u201332.","journal-title":"Gastroenterology"},{"issue":"8","key":"868_CR19","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/j.csda.2010.02.019","volume":"54","author":"F Konietschke","year":"2010","unstructured":"Konietschke F, Bathke AC, Hothorn LA, Brunner E. Testing and estimation of purely nonparametric effects in repeated measures designs. Computational Statistics & Data Analysis. 2010;54(8):1895\u2013905.","journal-title":"Computational Statistics & Data Analysis"},{"key":"868_CR20","doi-asserted-by":"crossref","unstructured":"Noguchi K, Gel YR, Brunner E, et al. nparLD: An R Software Package for the Nonparametric Analysis of Longitudinal Data in Factorial Experiments. J Stat Softw. 2012;50(12).","DOI":"10.18637\/jss.v050.i12"},{"issue":"12","key":"868_CR21","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1097\/MIB.0000000000000561","volume":"21","author":"E Shelton","year":"2015","unstructured":"Shelton E, Allegretti JR, Stevens B, et al. Efficacy of Vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort. Inflamm Bowel Dis. 2015;21(12):2879\u201385.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"868_CR22","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/MIB.0b013e31828100a4","volume":"19","author":"P Biancheri","year":"2013","unstructured":"Biancheri P, Di Sabatino A, Rovedatti L, et al. Effect of tumor necrosis factor-alpha blockade on mucosal addressin cell-adhesion molecule-1 in Crohn's disease. Inflamm Bowel Dis. 2013;19(2):259\u201364.","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"868_CR23","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/mnfr.200700156","volume":"52","author":"MD Kappelman","year":"2008","unstructured":"Kappelman MD. Bousvaros a nutritional concerns in pediatric inflammatory bowel disease patients. Mol Nutr Food Res. 2008;52(8):867\u201374.","journal-title":"Mol Nutr Food Res"},{"issue":"4","key":"868_CR24","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1097\/00005176-199904001-00009","volume":"28","author":"AM Griffiths","year":"1999","unstructured":"Griffiths AM, Nicholas D, Smith C, et al. Development of a quality-of-life index for pediatric inflammatory bowel disease: dealing with differences related to age and IBD type. J Pediatr Gastroenterol Nutr. 1999;28(4):S46\u201352.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"8","key":"868_CR25","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699\u2013710.","journal-title":"N Engl J Med"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-018-0868-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12876-018-0868-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-018-0868-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T13:37:15Z","timestamp":1568986635000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-018-0868-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,15]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["868"],"URL":"https:\/\/doi.org\/10.1186\/s12876-018-0868-x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734023680.793568153","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,15]]},"assertion":[{"value":"20 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local ethics committee (Ethikkommission der Medizinischen Universit\u00e4t Innsbruck, Innrain 43 A-6020 Innsbruck <i>No 1140\/2017<\/i>). All participants or their parental guardians signed to agree to use data for prospective analysis, without any individual person\u2019s data in any form (including individual details, images or videos).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Daniel Weghuber received a grant from Takeda Medical (Osaka, Japan). All data were generated as part of routine clinical practices, and were analysed independently for the purpose of this study.All other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"140"}}